Fiduciary Financial Group LLC Grows Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Fiduciary Financial Group LLC boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,556 shares of the specialty pharmaceutical company’s stock after buying an additional 279 shares during the quarter. Fiduciary Financial Group LLC’s holdings in Jazz Pharmaceuticals were worth $275,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Rise Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 203 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $108.80 on Friday. The firm has a 50 day moving average of $110.60 and a two-hundred day moving average of $109.90. The stock has a market capitalization of $6.86 billion, a PE ratio of 22.43, a P/E/G ratio of 1.34 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. On average, research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. UBS Group reduced their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Robert W. Baird reduced their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.14.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.